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Background: A prospective, single-arm, open-label, nonrandomized phase II combination chemotherapy with
cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus radioimmunotherapy trial was conducted to
evaluate the efficacy and safety in untreated elderly diffuse large B-cell lymphoma (DLBCL) patients.
Patients and methods: From February 2005 to April 2006, in our institute we treated 20 eligible elderly (age ‡60
years) patients with previously untreated DLBCL using a novel regimen consisting of six cycles of CHOP
chemotherapy followed 6–10 weeks later by 90Y ibritumomab tiuxetan.
Results: The overall response rate to the entire treatment regimen was 100%, including 95% complete remission
(CR) and 5% partial remission. Four (80%) of the five patients who achieved less than a CR with CHOP improved their
remission status after radioimmunotherapy. With a median follow-up of 15 months, the 2-year progression-free
survival was estimated to be 75%, with a 2-year overall survival of 95%. The 90Y ibritumomab tiuxetan toxicity included
grade ‡3 hematologic toxicity in 12 of 20 patients; the most common grade ‡3 toxic effects were neutropenia (12
patients) and thrombocytopenia (7 patients). Transfusions of red blood cells and/or platelets were given to one patient.
Conclusion: This study has established the feasibility, tolerability, and efficacy of this regimen for elderly patients with
DLBCL.
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introduction
Curative treatment is a perfectly valid option for elderly
patients with diffuse large B-cell lymphoma (DLBCL),
although the prognosis worsens with increasing age. Only in
cases where a careful examination of the patient and his
concomitant diseases indicates that full-dose therapy may
carry an unacceptable risk can a palliative treatment
approach be justified. Considering the combination
chemotherapy with cyclophosphamide, doxorubicin,
vincristine, and prednisone (CHOP) regimen as the reference
therapy [1] for the treatment of DLBCL, when CHOP is used at
lower doses in the elderly, the remission rate declines and
survival shortens compared with results in patients aged
<60 years [2]. The standard CHOP regimen, on the other
hand, achieves similar progression-free survival (PFS) to
that achieved in younger patients, but carries a much higher
risk of severe toxicity or death: 15%–30% in various
different retrospective series.
Recently, a combination of rituximab plus standard CHOP
regimen has become the standard for treating elderly patients
with DLBCL. This combination of eight cycles of
chemoimmunotherapy every 3 weeks has proved superior to
CHOP alone [3–5]. It increases the ‘complete’ response rate,
decreases the relapse rate, as well as prolonging event-free
survival, disease-free survival, and overall survival (OS).
Improving on these results, however, poses several questions:
the number of cycles (six or eight), the dose-dense regimen
(CHOP-14 instead of conventional CHOP-21), and the role of
radioimmunotherapy.
Pfreundschuh et al. conducted the RICOVER-60 trial in
which patients were randomly assigned to receive to receive six
or eight cycles of CHOP-14, with or without eight infusions of
rituximab. The investigators concluded that six cycles of
rituximab–CHOP-14 should be used in preference to eight cycles
of rituximab–CHOP-21 in elderly patients with DLBCL [6].
Radioimmunotherapy has emerged as an important
treatment option for patients with B-cell non-Hodgkin’s
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lymphoma. 90Y ibritumomab is a murine monoclonal
immunoglobulin G1 kappa antibody to CD20, a surface antigen
that is expressed on 90% of B-cell lymphomas [7] and
conjugated to the metal chelator tiuxetan for retention of the
beta emitter 90Y for therapy. Thus, treatment with 90Y
ibritumomab tiuxetan targets radiation to B-cell lymphomas,
which are inherently sensitive to radiation [8].
In the initial phase I–II trial of 90Y ibritumomab tiuxetan,
responses were seen in 43% of the 14 patients with DLBCL,
including complete remissions (CRs) in 29% [9]. Gordon et al.
[10] provided additional data supporting the safety and
activeness of 90Y ibritumomab tiuxetan in patients with
DLBCL. In the 12 patients in this phase I–II trial who had
a median of two prior regimens, the response rate was 58%,
including 33% CRs. A multicenter phase II study in Europe
has asessed the role of 90Y ibritumomab tiuxetan in 104
patients with relapsed or refractory elderly patients with
DLBCL who were not eligible for high-dose treatment,
mainly because of advanced age [11]. The overall response
rate was 44% and was noted to be higher in patients who had
not had prior therapy with rituximab compared with those
who had been previously treated with rituximab and
chemotherapy as their primary treatment; prior rituximab
exposure was one among other possible explanations for the
lower response after radioimmunotherapy since this subset of
patient with prior rituximab also was the one with the highest
proportion of primary refractory disease and poor prognostic
features.
In view of these findings, we decided to investigate the
efficacy and safety of a novel approach combining induction
chemotherapy with CHOP followed by consolidation with 90Y
ibritumomab tiuxetan, in a phase II trial for elderly patients
with previously untreated DLBCL.
patients and methods
patient eligibility
Patients older than 60 years of age with biopsy-proven, untreated
bidimensionally measurable stage II, stage III, or stage IV DLBCL
expressing the CD20 antigen were eligible for this trial if they had a World
Health Organization (WHO) performance status of zero to two. All
patients were notified of the investigational nature of this study and signed
a written informed consent approved in accordance with institutional
guidelines, including the Declaration of Helsinki. The study was approved
by the institutional review board.
All diagnostic biopsies were reviewed by an expert pathologist (SP) from
our institute to check the diagnosis of DLBCL according to the WHO
classification [12].
baseline studies
All patients entered in this trial were required to undergo a full history,
physical examination, complete blood cell count with differential leukocyte
count, platelet count, computed tomography (CT) scan of the neck, chest,
abdomen, and pelvis, positron emission tomography (PET) scan and
bone marrow aspiration, and biopsy. As per good medical practice, patients
were also tested for blood chemistry (including creatinine clearance, liver
function tests, uric acid, and lactate dehydrogenase) and underwent
urinanalysis and electrocardiography. Patients with a history of impaired
cardiac status were assessed by echocardiograph and were only eligible if the
cardiac ejection fraction was normal.
treatment plan
Patients were treated by standard CHOP chemotherapy every 21 days for
six cycles. Dosages of 750 mg/m2 cyclophosphamide, 50 mg/m2
doxorubicin, and 1.4 mg/m2 (maximum 2.0 mg) vincristine were
administered i.v. on day 1, and 100 mg prednisone was given orally daily
for 5 days each cycle. Allopurinol (300 mg orally) was recommended as
an adjunctive therapy for patients with bulky disease. If there were
<1500/ll granulocytes or <100 000/ll platelets by the time the next cycle
was due, treatment was delayed for 1 week and counts were repeated. If
counts had not recovered after 2 weeks, the patient was treated at 75%
of the last dose of cyclophosphamide and doxorubicine received.
Reescalation was at the discretion of the treating physician. Growth-
stimulating factors were not administered in order to prevent neutropenia,
but patients who experienced grade 3 or 4 neutropenia or developed
neutropenic fever between cycles of chemotherapy were allowed to
receive growth factors for subsequent cycles of therapy at the discretion
of the treating physician.
restaging
Patients were restaged 4–6 weeks after completion of the sixth cycle of
CHOP chemotherapy with physical examination, blood testing, CT scan,
PET scan and bone marrow aspiration, and biopsy. Patients achieving at
least a partial response after six cycles of CHOP were eligible for
consolidation with 90Y ibritumomab tiuxetan provided the granulocyte
count was >1500/ll granulocytes, the platelet count exceeded 100 000/ll,
and the bone marrow examination on completion of CHOP chemotherapy
showed no more than a 25% involvement with lymphoma.
Six to 10 weeks after completing the sixth cycle of CHOP chemotherapy,
the eligible patients were treated with one course of 90Y ibritumomab
tiuxetan (Figure 1), consisting of an initial infusion of rituximab 250 mg/
m2 on day 1 and then on days 7, 8, or 9; a second infusion of rituximab
250 mg/m2 was followed by a weight-based dose of 90Y ibritumomab
tiuxetan (provided by Bayer Schering Pharma, Berlin, Germany), given as
a slow i.v. bolus >10 min. The dose of 90Y ibritumomab tiuxetan was
11.1 MBq/kg (0.3 mCi/kg) in patients with a pretreatment platelet count
of 100 000–149 000/ll and 14.8 MBq/kg (0.4 mCi/kg) in those with
a count of 150 000/ll or higher. In all cases, the maximum total dose
was 1184 MBq (32 mCi).
90Y ibritumomab tiuxetan was routinely administered on an outpatient
basis in view of the lack of gamma emissions.
Disease status was evaluated by using physical examination, bone
marrow biopsy, a computer tomography scan of the neck, chest, abdomen,
and pelvis, and PET scan as well as other clinically relevant information.
This assessment was repeated 3 months after 90Y ibritumomab tiuxetan
infusion.
Figure 1. The combination chemotherapy with cyclophosphamide,
doxorubicin, vincristine, and prednisone (CHOP) and 90Y ibritumomab
tiuxetan regimen.
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Safety and tolerability were assessed by monitoring the incidence,
severity, and type of any adverse event. Adverse events were graded
according to the Common Toxicity Criteria.
Responses were classified according to the International Workshop
Response Criteria [13].
statistical analysis
The primary end point of this study was the complete response rate
(including PET evaluation) associated with CHOP plus
radioimmunotherapy.
Sample size estimation was carried out by Fleming’s single-stage
procedure [14, 15]. Previous experience shows that the response rate,
adjusted for the response criteria as in par, has been 50%. Defining p0 as the
proportion of response below the treatment that does not warrant further
investigations and pa as the proportion of responses beyond a phase III trial
should be carried out, we set p0 = 0.5 and pa = 0.8. The number of patients
required, given a type I error (a) at 0.05 two-sided and a power of 1–
b = 80%, is 18 and the number of successes (responses) 13. If, at the end of
the trial, at least 13 responses (successes) are observed, the treatment will be
accepted for a phase III trial [16]. OS and PFS curves were plotted by the
Kaplan–Meier method [17]. PFS was defined as the time from registration
to the first observation of progressive disease or death as a result of any
cause.
results
patient characteristics
Twenty patients were registered in this trial from February 2005
to April 2006 when the study reached completion and was
closed. The patients’ characteristics are listed in Table 1. The
median age of patients on the trial was 68 years, with a range of
61–84 years. Twelve (60%) were male and eight (40%) were
female. Six patients were stage II and 14 stage III–IV. Two
patients (10%) had bulky disease. Globally, 16 patients were
intermediate and high risk according to the International
Prognostic Index score [18].
clinical response
All patients completed the CHOP and 90Y ibritumomab
tiuxetan protocol. There is no record of any patient receiving
a reduced dose of 90Y ibritumomab tiuxetan because of the
persisting thrombocytopenia following CHOP.
The overall response rate to the entire treatment regimen was
100%, including 95% CR and 5% partial remission (PR).
Therapy with 90Y ibritumomab tiuxetan substantially improved
CR rate (Table 2). Of the five patients initially with a PR on
CHOP regimen alone, addition of 90Y ibritumomab tiuxetan
improved the overall best response (from PR to CR) in four
(80%); this evaluation was done utilizing CT and PET scans; all
these four patients achieved a PET negativity after
radioimmunotherapy.
With a median follow-up time of 15 months, 3 of 20 eligible
patients have experienced progression or died, yielding an
estimated 2-year PFS rate of 75% (Figure 2). One patient died
because of lymphoma progression; the 2-year estimate of OS
was 95% (Figure 2). Regarding the three patients who
progressed or died, after CHOP alone two had obtained PR
(one high-risk and one low-risk IPI, respectively) and one a CR
(low-risk IPI); subsequently, after 90Y ibritumomab tiuxetan
two of them were in CR (PET negativity) and one in PR (the
high-risk IPI one had achieved a PR with CHOP alone).
safety
There were no treatment-related deaths. The CHOP regimen
was well tolerated by most patients. Reversible hematologic
toxic effects constituted most of the adverse events, including
grade 4 hematologic toxicity in 3 (15%) patients and grade 3
Table 1. Patients’ characteristics (n = 20)
Median age, years (range) 68 (61–84)
Sex, n (%)
Male 12 (60)
Female 8 (40)
Symptoms, n (%)
A 18 (90)
B 2 (10)
Bulky disease, n (%)
Yes 2 (10)
No 18 (90)
LDH level, n (%)
Elevated 16 (80)
Normal 4 (20)
Stage, n (%)
II 6 (30)
III 5 (25)
IV 9 (45)
IPI score, n (%)
0–1 5 (25)
‡2 15 (75)
LDH, lactate dehydrogenase; IPI, International Prognostic Index.
Table 2. Response to therapy
Response After CHOP
n (%)
After CHOP + 90Y
ibritumomab tiuxetan
n (%)
Complete remission 15 (75) 19 (95)
Partial remission 5 (25) 1 (5)
CHOP, combination chemotherapy with cyclophosphamide, doxorubicin,
vincristine, and prednisone.
Figure 2. Overall survival (solid line) and progression-free survival
(dotted line) curves of all 20 patients.
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hematologic toxicity in 10 (50%) patients. It was noted that all
these patients presented neutropenia. Three patients (15%)
developed febrile neutropenia, and two of them were
hospitalized due to febrile neutropenia. Two (10%) patients
experienced grade 2 nausea and vomiting and one (5%) patient
had grade 3 neuropathy.
regarding 90Y ibritumomab tiuxetan, there were no
infusion-related reactions
Adverse events after 90Y ibritumomab tiuxetan treatment were
primarily hematologic and transient; no patient discontinued
treatment because of an adverse event. The duration of
hematologic toxicity is listed in Table 3. Grade 3–4
thrombocytopenia and neutropenia occurred in 7 patients
(37%) and 12 patients (58%), respectively. Two patients (10%)
received granulocyte colony-stimulating factors; only one
patient (5%) received platelet transfusions, and none received
red blood cell transfusions.
No patient developed elevated thyroid-stimulating hormone
levels and any secondary malignancies.
discussion
This study has established the feasibility, tolerability, and
efficacy of sequential treatment with six cycles of CHOP
chemotherapy followed by 90Y ibritumomab tiuxetan as front-
line therapy for untreated elderly DLBCL patients. Patients up
to age 84 tolerated the sequential treatment regimen well.
The clinical evaluation of immunotherapy on the basis of
anti-CD20 monoclonal antibodies has markedly affected the
treatment approach for elderly patients with DLBCL.
Rituximab is widely employed as a treatment administered
alone or in combination with chemotherapy. In parallel,
radioimmunotherapy with 90Y ibritumomab tiuxetan has been
developed and proves to be among the most active agents in
lymphoma therapy. Its toxicity is manageable and consists
primarily of transient myelosuppression in addition to the
typical antibody-associated infusion reactions. Clinical trials
with this agent have shown significant activity in transformed
B-cell non-Hodgkin’s lymphoma and in DLBCL [9, 10],
including disease that is resistant to chemotherapy or unlabeled
rituximab [11].
The data have demonstrated that a substantial proportion of
patients can have durable remissions, extending in some cases
longer than 3 years. On the basis of these data, further
investigations are monitoring radioimmunotherapy either as
a stand-alone initial treatment [19] or as a consolidation after
initial treatment with chemotherapy (with or without
rituximab) [20–22]. Initial reports from these studies have
shown acceptable toxicity with promising antilymphoma
activity, and randomized studies are in progress. The principal
challenge when it comes to applying these radiolabeled
immunotherapies is how to integrate them into the treatment
approach in the most effective manner. The fact that
radioimmunotherapy has demonstrated the highest response
rate of any ‘single-agent’ approach in lymphoma therapy
highlights the potential importance attaching to this
therapeutic modality.
The reason why we decided to conduct this sequential
treatment utilizing conventional chemotherapy followed by
radioimmunotherapy (90Y ibritumomab tiuxetan) was to test
its degree of activeness and safety in this particular subset of
elderly patients. By the end of sequential combined treatment,
19 (95%) had achieved CR and the remaining patient had PR.
More importantly, among the five patients who achieved a PR
with CHOP, four (80%) improved their remission status after
treatment with 90Y ibritumomab tiuxetan.
Toxic effects were generally mild without any aspect of
cumulative toxicity. Hematologic toxicity was moderate with
90Y ibritumomab tiuxetan, following six cycles of CHOP and
rarely led to infection or required transfusion support. On the
other hand, non-hematologic toxicity was practically absent
with 90Y ibritumomab tiuxetan.
Because this novel sequential treatment appears promising
compared with the literature data on the combination of
CHOP plus rituximab, we are currently carrying out a trial with
CHOP plus rituximab followed by 90Y ibritumomab tiuxetan in
untreated elderly DLBCL patients, reducing the number of
CHOP cycles from six to four, with a rituximab administration
for each CHOP cycle. The rationale is to utilize all the
therapeutical approaches—chemotherapy, immunotherapy,
radioimmunotherapy—reducing conventional chemotherapy
and probably its related toxicity, hematologic and non-
hematologic, in elderly patients. In addition, CHOP plus
rituximab followed by 90Y ibritumomab tiuxetan is certainly
a sequence to be tested in a proper phase III, but the
comparative efficacy (with CHOP-14 plus rituximab) can
only be assessed in this trial.
funding
BolognAIL.
Table 3. Hematologic toxicity post radioimmunotherapy
Variable Baseline Nadir (range) Days from baseline
to nadir
Median duration for
patients with grade
3 or 4 nadir (days)
ANC, cells/mm3 3300 (1600–5460) 800 (255–3000) 39 (20–60) 32 (10–66)
Platelets, cells/mm3 217 (150–500) 42 (9–187) 35 (20–43) 22 (10–49)
Hemoglobin, g/dl 13.5 (12–14.5) 11.8 (8.7–14.2) 43 (20–60) –
ANC, absolute neutrophil count.
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